Therefore, in the process of using HSP-Exs as tools for actual tumor therapy, a strategy should be selected according to the specific type of cancer, and the elucidation of the immunostimulatory mechanism of exosomes, which ensures that HSP-Exs can be carriers of antigens and adjuvants for cancer vaccines, is crucial. The gene discussed is HSP90B2P; the disease is neoplasm.